VIVIO Extends Open Market Specialty Drug Platform to Solve Our PBM Crisis

During a landmark webinar this week, VIVIO, a Public Benefit Corporation, announced PrecisionCare One™, an extension of its proven open-market specialty drug management platform to include all drugs. This builds on VIVIO’s prior success in managing complex specialty medications across pharmacy and medical benefits, where its clinical-first approach has delivered cost-effective outcomes in oncology, rheumatology, multiple sclerosis, HIV, and other specialized therapeutic areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125851504/en/

Pramod John, CEO, VIVIO (Photo: Business Wire)

Pharmacy Benefit Managers (PBMs) have long positioned themselves as cost-reduction champions. Instead, their opaque practices have systematically inflated medication costs through hidden fees, rebate manipulation, and anti-competitive pricing strategies. These expensive intermediaries have siphoned billions from healthcare, failing patients and employers alike.

"We've demonstrated that combining deep clinical expertise with open market economics works for the most complex medications. Now we're expanding this model for all drugs," said Pramod John, VIVIO's CEO. "It isn't that we need better PBMs; we just don't need their model anymore."

The expanded platform includes VIVIO's latest innovation: a comprehensive clinical management program for GLP-1 medications. This program addresses one of healthcare's fastest-growing cost drivers and applies the same rigorous, evidence-based approach that has long distinguished VIVIO's specialty drug management.

As open markets revolutionized retail, transportation, travel, and other industries, VIVIO is applying these same transformative principles to healthcare. "Buying healthcare can be as straightforward as purchasing any other good or service," John continued. "We're fixing the broken system by eliminating discount guarantees, exclusive formularies, and rebate schemes that artificially inflate prices, reduce competition, and compromise health outcomes."

Mark Cuban, who co-presented at the webinar, emphasized the urgency of this mission: "Nobody looks at healthcare and says, 'This is an efficient market.' What VIVIO and Cost Plus Drugs are doing can fundamentally reshape healthcare for the entire country."

VIVIO's first PrecisionCare One customer, Lake County Schools, embodies the frustration with traditional PBM models. "We were tired of playing the rebate shell game," said Director of Risk Management Robert Oyer. "The only way to know if we are saving real dollars is to have verifiable unit costs."

VIVIO's approach doesn't eliminate nuance—it eliminates waste. By applying open market principles and providing complete visibility into costs and decision-making, the platform replaces unnecessary complexity with intelligent simplicity while maintaining the sophisticated data-driven clinical oversight that has been the hallmark of VIVIO's specialty drug management success.

PrecisionCare One is more than just a new product—it's a plug-and-play solution built on open-market principles and data-driven clinical models designed to redefine healthcare economics. Extending its transformation of the specialty drug space, VIVIO is now poised to revolutionize the entire pharmacy benefits industry with a common-sense procurement approach to drugs—a long overdue change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125851504/en/